• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓灰质炎病毒免疫与传播专家综述。

Expert review on poliovirus immunity and transmission.

机构信息

Kid Risk, Inc., P.O. Box 590129, Newton, MA, USA.

出版信息

Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15.

DOI:10.1111/j.1539-6924.2012.01864.x
PMID:22804479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7896540/
Abstract

Successfully managing risks to achieve wild polioviruses (WPVs) eradication and address the complexities of oral poliovirus vaccine (OPV) cessation to stop all cases of paralytic poliomyelitis depends strongly on our collective understanding of poliovirus immunity and transmission. With increased shifting from OPV to inactivated poliovirus vaccine (IPV), numerous risk management choices motivate the need to understand the tradeoffs and uncertainties and to develop models to help inform decisions. The U.S. Centers for Disease Control and Prevention hosted a meeting of international experts in April 2010 to review the available literature relevant to poliovirus immunity and transmission. This expert review evaluates 66 OPV challenge studies and other evidence to support the development of quantitative models of poliovirus transmission and potential outbreaks. This review focuses on characterization of immunity as a function of exposure history in terms of susceptibility to excretion, duration of excretion, and concentration of excreted virus. We also discuss the evidence of waning of host immunity to poliovirus transmission, the relationship between the concentration of poliovirus excreted and infectiousness, the importance of different transmission routes, and the differences in transmissibility between OPV and WPV. We discuss the limitations of the available evidence for use in polio risk models, and conclude that despite the relatively large number of studies on immunity, very limited data exist to directly support quantification of model inputs related to transmission. Given the limitations in the evidence, we identify the need for expert input to derive quantitative model inputs from the existing data.

摘要

成功管理风险以实现野生脊灰病毒(WPV)根除,并应对停用口服脊灰病毒疫苗(OPV)以停止所有麻痹性脊髓灰质炎病例的复杂性,这强烈依赖于我们对脊灰病毒免疫和传播的集体理解。随着越来越多的人从 OPV 转向灭活脊灰病毒疫苗(IPV),许多风险管理选择促使我们需要了解权衡和不确定性,并开发模型以帮助做出决策。美国疾病控制与预防中心于 2010 年 4 月召集了一次国际专家会议,以审查与脊灰病毒免疫和传播相关的现有文献。本次专家审查评估了 66 项 OPV 挑战研究和其他证据,以支持开发脊灰病毒传播和潜在暴发的定量模型。本综述重点介绍了暴露史对易感性、排泄持续时间和排泄病毒浓度的免疫特征。我们还讨论了宿主对脊灰病毒传播的免疫力减弱的证据、排泄的脊灰病毒浓度与传染性之间的关系、不同传播途径的重要性以及 OPV 和 WPV 之间的传播差异。我们讨论了在脊灰风险模型中使用现有证据的局限性,并得出结论,尽管有大量关于免疫的研究,但非常有限的数据直接支持与传播相关的模型输入的量化。鉴于证据的局限性,我们确定需要专家的投入,以便从现有数据中推导出定量模型输入。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/8e4ea40f2fa5/nihms-1669917-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/46d4dd38eeaa/nihms-1669917-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/461b68d29c14/nihms-1669917-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/3812884c3251/nihms-1669917-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/f4b572e3487a/nihms-1669917-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/9e59d31b5daa/nihms-1669917-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/c913a457ab0e/nihms-1669917-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/8e4ea40f2fa5/nihms-1669917-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/46d4dd38eeaa/nihms-1669917-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/461b68d29c14/nihms-1669917-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/3812884c3251/nihms-1669917-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/f4b572e3487a/nihms-1669917-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/9e59d31b5daa/nihms-1669917-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/c913a457ab0e/nihms-1669917-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9db/7896540/8e4ea40f2fa5/nihms-1669917-f0007.jpg

相似文献

1
Expert review on poliovirus immunity and transmission.脊髓灰质炎病毒免疫与传播专家综述。
Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15.
2
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.脊髓灰质炎病毒免疫和传播的回顾与评估:知识空白的综合分析与研究需求的确定。
Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28.
3
Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.管理人群免疫力,以降低或消除脊髓灰质炎病毒输入后传播的风险。
Vaccine. 2015 Mar 24;33(13):1568-77. doi: 10.1016/j.vaccine.2015.02.013. Epub 2015 Feb 18.
4
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.用于预防脊髓灰质炎的序贯灭活脊髓灰质炎疫苗(IPV)和口服脊髓灰质炎减毒活疫苗(OPV)
Cochrane Database Syst Rev. 2019 Dec 5;12(12):CD011260. doi: 10.1002/14651858.CD011260.pub2.
5
Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.消灭脊灰:全世界的儿科医生如何助力永远终结这种致残疾病
Pediatrics. 2015 Jan;135(1):196-202. doi: 10.1542/peds.2014-3163.
6
Anomalous observations on IPV and OPV vaccination.关于脊灰灭活疫苗(IPV)和口服脊髓灰质炎疫苗(OPV)接种的异常观察结果。
Dev Biol (Basel). 2001;105:197-208.
7
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).口服脊髓灰质炎疫苗的演变及其对模拟循环疫苗衍生脊髓灰质炎病毒(cVDPV)风险的启示。
Risk Anal. 2013 Apr;33(4):680-702. doi: 10.1111/risa.12022. Epub 2013 Mar 7.
8
Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.三价口服脊髓灰质炎疫苗停用和灭活脊髓灰质炎疫苗引入-全球,2016 年。
MMWR Morb Mortal Wkly Rep. 2016 Sep 9;65(35):934-8. doi: 10.15585/mmwr.mm6535a3.
9
Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.口服脊髓灰质炎疫苗病毒的传播性与持久性:对全球根除脊髓灰质炎行动的影响
Am J Epidemiol. 1999 Nov 15;150(10):1001-21. doi: 10.1093/oxfordjournals.aje.a009924.
10
Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.建立模型的策略,以提高人口免疫力并预防尼日利亚西北部高危地区的脊髓灰质炎病毒传播。
J Infect Dis. 2014 Nov 1;210 Suppl 1:S412-23. doi: 10.1093/infdis/jit834.

引用本文的文献

1
Advances and challenges in poliomyelitis vaccines: a comprehensive review of development, production, and global deployment.脊髓灰质炎疫苗的进展与挑战:对其研发、生产及全球部署的全面综述
Front Public Health. 2025 Jul 16;13:1611028. doi: 10.3389/fpubh.2025.1611028. eCollection 2025.
2
Assessing early detection ability through spatial arrangements in environmental surveillance for poliovirus: A simulation-based study.通过脊髓灰质炎病毒环境监测中的空间布局评估早期检测能力:一项基于模拟的研究
PLoS One. 2025 Jul 9;20(7):e0325789. doi: 10.1371/journal.pone.0325789. eCollection 2025.
3
Characterization of environmental and clinical surveillance inputs to support prospective integrated modeling of the polio endgame.支持脊髓灰质炎终结阶段前瞻性综合建模的环境与临床监测数据特征分析
PLOS Glob Public Health. 2025 Feb 7;5(2):e0004168. doi: 10.1371/journal.pgph.0004168. eCollection 2025.
4
A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.一项关于荷兰国家免疫规划的文献综述及基于证据的评估揭示了改进的可能性。
Vaccine X. 2024 Sep 26;20:100556. doi: 10.1016/j.jvacx.2024.100556. eCollection 2024 Oct.
5
An automated assay platform for the evaluation of antiviral compounds against polioviruses.一种用于评估抗脊髓灰质炎病毒化合物的自动化分析平台。
J Virol Methods. 2024 Sep;329:115006. doi: 10.1016/j.jviromet.2024.115006. Epub 2024 Aug 8.
6
Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.不同脊髓灰质炎疫苗选择在应对美国和其他仅在常规免疫中使用灭活脊髓灰质炎疫苗(IPV)的国家的脊髓灰质炎疫情中的权衡。
Vaccine. 2024 Feb 6;42(4):819-827. doi: 10.1016/j.vaccine.2023.12.081. Epub 2024 Jan 12.
7
Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.在停止口服脊髓灰质炎疫苗(OPV)接种后,国家免疫规划中重新启动OPV相关选项的复杂性。
Gates Open Res. 2023 Apr 17;7:55. doi: 10.12688/gatesopenres.14511.1. eCollection 2023.
8
Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China.中国杭州不同灭活脊灰疫苗免疫程序的成本效果分析。
Front Public Health. 2022 Sep 23;10:990042. doi: 10.3389/fpubh.2022.990042. eCollection 2022.
9
Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.消灭脊髓灰质炎终局疫苗选择的卫生经济学分析:2022-2036 年。
Expert Rev Vaccines. 2022 Nov;21(11):1667-1674. doi: 10.1080/14760584.2022.2128108. Epub 2022 Oct 5.
10
Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020.2020 年,也门萨达省循环疫苗衍生脊髓灰质炎病毒 1 型暴发。
BMC Infect Dis. 2022 Apr 29;22(1):414. doi: 10.1186/s12879-022-07397-0.

本文引用的文献

1
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.脊髓灰质炎病毒免疫和传播的回顾与评估:知识空白的综合分析与研究需求的确定。
Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28.
2
Preeradication vaccine policy options for poliovirus infection and disease control.消灭前脊灰病毒感染和疾病控制的疫苗政策选择。
Risk Anal. 2013 Apr;33(4):516-43. doi: 10.1111/risa.12019. Epub 2013 Mar 5.
3
Modeling population immunity to support efforts to end the transmission of live polioviruses.建立人群免疫模型以支持消灭活脊髓灰质炎病毒传播的努力。
Risk Anal. 2013 Apr;33(4):647-63. doi: 10.1111/j.1539-6924.2012.01891.x. Epub 2012 Sep 17.
4
Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.当前全球消灭脊灰和控制政策选择:模型视角和停用口服脊灰疫苗的前提条件。
Expert Rev Vaccines. 2012 Apr;11(4):449-59. doi: 10.1586/erv.11.195.
5
Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.单价 1 型口服脊髓灰质炎疫苗在印度婴儿中的应用:两项随机、双盲、对照临床试验报告。
Vaccine. 2011 Aug 5;29(34):5793-801. doi: 10.1016/j.vaccine.2011.04.133.
6
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.二价 1 型和 3 型口服脊髓灰质炎疫苗的免疫原性:一项随机、双盲、对照试验。
Lancet. 2010 Nov 13;376(9753):1682-8. doi: 10.1016/S0140-6736(10)61230-5. Epub 2010 Oct 25.
7
Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics.开发基于个体的脊髓灰质炎病毒模型:网络类型和结果指标选择的影响。
Epidemiol Infect. 2011 Jun;139(6):836-48. doi: 10.1017/S0950268810001676. Epub 2010 Jul 12.
8
Fractional doses of inactivated poliovirus vaccine in Oman.阿曼的脊髓灰质炎灭活疫苗小剂量接种。
N Engl J Med. 2010 Jun 24;362(25):2351-9. doi: 10.1056/NEJMoa0909383.
9
Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.印度接种单价和三价口服脊髓灰质炎疫苗后的黏膜免疫。
J Infect Dis. 2009 Sep 1;200(5):794-801. doi: 10.1086/605330.
10
Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine.新生儿接种单价1型口服脊髓灰质炎疫苗后,疫苗病毒的脱落以及抗原性和基因差异增加。
J Virol. 2009 Sep;83(17):8693-704. doi: 10.1128/JVI.02388-08. Epub 2009 Jun 10.